期刊文献+

丹参对实验性动脉粥样硬化形成的预防 被引量:57

Effect of danshen on experimental atherosclerosis
原文传递
导出
摘要 目的:探讨丹参抑制动脉粥样硬化(AS)作用中的可能的分子机制。方法:随机将21只家兔均分为 对照组、AS组和丹参干预组,采用高脂饲料建立AS模型,9周后行血脂测定、主动脉粥样斑块面积计算,并以逆 转录 聚合酶链式反应(RT PCR)分别进行三组的单核细胞趋化蛋白 1(MCP 1)mRNA表达水平测定,以及用免 疫组织化学方法对比各组MCP 1蛋白表达。结果:对照组和丹参组中血脂水平和主动脉粥样斑块面积低于AS 组(P<0.01);主动脉血管内皮细胞以及平滑肌细胞内MCP 1mRNA水平及蛋白表达水平在对照组和丹参组中 明显低于AS组(P<0.01)。结论:丹参能降低MCP 1表达水平,这可能是其抑制AS形成的分子学机制之一。 Objective:To explore the molecular mechanism of danshen in experimental atherosclerosis(AS). Method:Twenty-one normal male rabbits were randomly divided into three groups: normal control group, AS group and danshen treating group. Hyperlipidic feed was adopted to build the atherosclerotic animal model. Meanwhile, we used Danshen to intervene atherosclerosis in the animal model. Serum lipids and aorta tissues were measured after nine weeks.The effect of Danshen on the level of Monocyte chemotatic protein-1 (MCP-1) mRNA expression and MCP-1 protein were observed and analyzed by means of reverse transcription-polymerase chain reaction assay (RT-PCR) and immunohistochemical method. Result: Serum TG and the aorta atherosclerosis area in normal group and danshen group were significantly lower than that in AS group (P< 0.01), MCP-1 expression was reduced in danshen group (P< 0.01). Conclusion:Danshen is able to reduce expression level of MCP-1, which is one of the possible molecular mechanisms in inhibiting atherosclerosis.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2005年第1期54-55,共2页 Journal of Clinical Cardiology
关键词 动脉粥样硬化 单核细胞趋化蛋白-1 丹参 Atherosclerosis Monocyte chemotatic protein-1 Danshen
  • 相关文献

参考文献5

二级参考文献8

  • 1王筠默.中药药理学[M].上海:上海科技技术出版社,1997.70-71.
  • 2耿贯一 主编.流行病学:第3版[M].北京:人民卫生出版社,1995.50-50.
  • 3Stanley W C, Lopaschuk G D, Hall J L. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res, 1997, 33 : 243-257.
  • 4Stanley W C, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: The pharmacologyof trimetazidine. Fundam Clin Pharmacol, 2003, 17:133--145.
  • 5Detry J M , Sellier P, Pennaforte S, et al. Trimetazidine: A new concept in the treatment of angina: comparison with propranolol in patients with stable angina.Br J Clin Pharmacol, 1994, 37:279--288.
  • 6Polonski L, Dec I, Wojnar R, et al. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin, 2002,18:389--396.
  • 7Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the pro-tective effect of trimetazidine on rat cardiomyocytes during hypoxia and re-oxygenation. J Mol Cell Cardiol, 1994, 26:949--958.
  • 8Morin D, Elimadi A, Sapena R, et al. Evidence for theexistence of [^3H]-trimetazidine binding sites in volved inthe regulation of the mitochondrialperme ability transition pore. Br J Pharmacol, 1998, 123:1385--1394.

共引文献97

同被引文献479

引证文献57

二级引证文献740

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部